Stevia plant with high sweetness content and screening method thereof
By identifying and screening specific mutation sites in the genome of stevia plants, the content of sweet ingredients is improved, the problems of low production efficiency and high cost of sweet ingredients in stevia plants are solved, and efficient and low-cost sweet ingredients development are achieved .
Patent Information
- Application Number
- CN201980049512.8
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2019-07-30
- Publication Date
- 2024-11-29
- Estimated Expiration
- 2039-07-30
AI Technical Summary
The prior art is difficult to efficiently screen and develop stevia plants with high sweet ingredient content, resulting in low production efficiency and high cost of sweet ingredient.
By detecting specific mutation sites in the genome of stevia plants, such as C to A mutations at position 49 of sequence number 1, individuals with high sweetness content were screened using PCR amplification and dCAPS method, and improving through hybridization Content of sweet ingredients.
It realizes low-cost and efficient screening and development of sweet ingredients, shortens the development time of stevia plants with high sweet ingredient content, and improves development success rate and production efficiency.
Smart Images

Figure BDA0002914126860000051 
Figure BDA0002914126860000221 
Figure HDA0002914126870000011
Abstract
Description
Technical Field
[0001] The present invention relates to a stevia plant with high sweet component content and a screening method thereof. Background Art
[0002] In order to meet the diverse needs of consumers, various beverages have been developed and marketed. Sugars such as sucrose are usually added to beverages for the purpose of imparting sweetness, but excessive intake has been pointed out to have an impact on health, and the demand for lower-calorie and naturally derived sweeteners is growing. For example, Patent Document 1 discloses a functional sweetener composition containing vitamins, high-intensity sweeteners, and a sweetness-improving composition.
[0003] Rebaudioside (hereinafter also referred to as "Reb") is well known as a sweet ingredient contained in stevia extract. Stevia extract is extracted and refined from dried stevia leaves. Stevia is a perennial plant of the Asteraceae family native to Paraguay, South America, and its scientific name is Stevia Rebaudiana Bertoni. Since stevia contains a component that is about 300 times sweeter than sugar, it is cultivated to extract the sweet component and use it as a natural sweetener. As Reb, various glycosides such as RebA, RebB, RebC, RebD, RebE, and RebM are reported (Japanese Patent Table 2012-504552). Among various Rebs, for example, RebA is evaluated as a sweetener with high sweetness and high-quality sweetness and is widely used. It is also being determined that other Rebs have their own unique sweetness and accompanying taste.
[0004] Under such circumstances, stevia plants having an increased content of specific rebaudioside are known (Patent Documents 2 to 4).
[0005] Prior art literature
[0006] Patent Literature
[0007] Patent Document 1: Japanese Patent Application No. 2009-517043
[0008] Patent Document 2: Japanese Patent Application No. 2016-515814
[0009] Patent Document 3 International Application Publication WO2016 / 090460
[0010] Patent Document 4 International Application Publication WO2018 / 124142 Summary of the invention
[0011] There is a growing demand for the sweetening properties of the stevia plant.
[0012] In one aspect, the present invention provides the following.
[0013] [1] A method for screening stevia plants high in sweet component content, comprising the step of detecting a mutation in a portion corresponding to sequence number 1 from the genome of a test stevia plant.
[0014] [2] The method according to [1], characterized in that the portion corresponding to sequence number 1 is a genomic portion of a test stevia plant amplified by PCR using a forward primer selected from sequence numbers 2 to 8 and a reverse primer selected from sequence numbers 9 to 15.
[0015] [3] The method according to [1] or [2], characterized in that the mutation includes a mutation from C to A in the site corresponding to position 49 of sequence number 1.
[0016] [4] The method according to any one of [1] to [3], wherein the step of detecting mutations is performed using a dCAPS method or a TaqMan PCR method.
[0017] [5] The method according to any one of [1] to [4], further comprising the step of measuring the sweet component content of the test stevia plant tissue in which the mutation has been detected.
[0018] [6] The method according to any one of [1] to [5], characterized in that the test stevia plant body belongs to an isolated group, which is obtained by mating parents at least one of which is a heterozygous parent having a mutation in the portion corresponding to sequence number 1, and the content of sweet components contained in the high-sweet component-containing stevia plant body is higher than the average value of the sweet component content of all individuals belonging to the aforementioned isolated group.
[0019] [7] The method according to any one of [1] to [6], wherein the sweet component includes steviol glycoside.
[0020] [8] The method according to any one of [1] to [7], wherein the stevia plant containing a high amount of sweet ingredients is a non-genetically modified plant.
[0021] [9] The method according to any one of [1] to [8], wherein the stevia plant to be tested includes a stevia plant that has been subjected to a mutagenesis treatment and its progeny plant.
[0022]
[10] A primer pair, characterized in that it comprises the following forward primer and reverse primer: the forward primer comprises a sequence selected from sequence numbers 47 to 70 located at the 3' end and any continuous sequence extending from position 28 of sequence number 1 to the 5' end and attached to the 5' end of the aforementioned sequence in an arbitrarily selected manner; the reverse primer comprises a sequence complementary to any continuous sequence of more than 20 bases located from position 50 of sequence number 1 to the 3' end.
[0023]
[11] A kit comprising the primer pair and restriction enzyme described in
[10] , characterized in that when the forward primer includes sequence number 47, the restriction enzyme is DdeI; when the forward primer includes sequence number 48, the restriction enzyme is MaeI or SpeI; when the forward primer includes sequence number 49, the restriction enzyme is AflII or MseI; when the forward primer includes sequence number 50, the restriction enzyme is Bce83I; when the forward primer includes sequence number 51, the restriction enzyme is Bse MII; when the forward primer includes sequence number 52, the restriction enzyme is BsiI; when the forward primer includes sequence number 53, the restriction enzyme is BspHI or Hpy178III; when the forward primer includes sequence number 54, the restriction enzyme is SfeI; when the forward primer includes sequence number 55, the restriction enzyme is SmlI; when the forward primer includes sequence number 56, the restriction enzyme is EcoP15I; when the forward primer includes sequence number 57, the restriction enzyme is AvaI; when the forward primer includes sequence number 58, the restriction enzyme is When the forward primer includes sequence number 58, the restriction enzyme is BclI; when the forward primer includes sequence number 59, the restriction enzyme is BseRI; when the forward primer includes sequence number 60, the restriction enzyme is CviRI or PstI; when the forward primer includes sequence number 61, the restriction enzyme is DrdII; when the forward primer includes sequence number 62, the restriction enzyme is Eco57I; when the forward primer includes sequence number 63, the restriction enzyme is GsuI; when the forward primer includes sequence number 64, the restriction enzyme is The enzyme is HphI; when the forward primer includes sequence number 65, the restriction enzyme is Hpy188I; when the forward primer includes sequence number 66, the restriction enzyme is MboII; when the forward primer includes sequence number 67, the restriction enzyme is Pfl1108I; when the forward primer includes sequence number 68, the restriction enzyme is PsiI; when the forward primer includes sequence number 69, the restriction enzyme is TaqI or XhoI; when the forward primer includes sequence number 70, the restriction enzyme is StySKI.
[0024]
[12] A plant body, which is a stevia plant body with a high sweet component content, characterized in that it has a mutation in the genome portion corresponding to sequence number 1.
[0025]
[13] The plant according to
[12] , characterized in that the mutation includes a mutation from C to A in the site corresponding to position 49 of sequence number 1.
[0026]
[14] The plant according to
[12] or
[13] , characterized in that it is a non-genetically modified plant.
[0027]
[15] A seed, tissue, dried leaf, tissue culture or cell, characterized in that it is the seed, tissue, dried leaf, tissue culture or cell of the plant according to any one of claims 12 to 14.
[0028]
[16] The tissue, tissue culture or cell according to
[15] , characterized in that it is selected from embryos, meristem cells, pollen, leaves, roots, root tips, petals, protoplasts, leaf sections and callus tissue.
[0029]
[17] A method for growing a stevia plant high in sweetness components, comprising the step of hybridizing the stevia plant according to any one of
[12] to
[14] with a second stevia plant.
[0030]
[18] The method according to
[17] , wherein the second plant is the Stevia plant according to any one of
[12] to
[14] .
[0031]
[19] A method for cultivating a stevia plant with a high sweet component content, characterized in that it includes a step of introducing a mutation from C to A at a site corresponding to position 49 of sequence number 1 in the genome of the stevia plant.
[0032]
[20] The method according to
[19] , characterized in that the introduction of mutation is carried out by mutagenesis treatment.
[0033]
[21] A method for producing a food or beverage, a sweetening composition, a spice or a pharmaceutical product, characterized in that it comprises the steps of providing an extract of the plant described in any one of
[12] to
[14] , the seed, tissue, dried leaf, tissue culture or cell described in
[15] , or the tissue, tissue culture or cell described in
[16] , and adding the aforementioned extract to the raw materials of the food or beverage, sweetening composition, spice or pharmaceutical product.
[0034] The present invention has one or more of the following effects.
[0035] (1) Stevia plants with high sweet component content can be screened at low cost.
[0036] (2) It can shorten the time required to develop stevia plants with high sweetness content.
[0037] (3) It can improve the success rate of developing stevia plants with high sweetness content.
[0038] (4) The production efficiency of sweet ingredients derived from stevia plants can be improved.
[0039] (5) The production cost of sweet ingredients derived from stevia plants can be reduced. BRIEF DESCRIPTION OF THE DRAWINGS
[0040] Figure 1 This is a graph showing the frequency distribution of the sweet component content in individuals of the M1 generation. The vertical axis represents the number of individuals, and the horizontal axis represents the sweet component concentration (%) in the dry leaves.
[0041] Figure 2 is the mutation C49A positive individual (C49A + ) and negative individuals (C49A - ) is a graph showing the distribution of the sweet component content in the dried leaves. The vertical axis represents the sweet component concentration (%) in the dry leaves, and the dotted line represents the average value of the sweet component concentration of all individuals belonging to the isolated group A.
[0042] Figure 3 is the mutation C49A positive individual (C49A + ) and negative individuals (C49A - ) is a graph showing the distribution of the sweet component content in the dried leaves. The vertical axis represents the sweet component concentration (%) in the dry leaves, and the dotted line represents the average value of the sweet component concentration of all individuals belonging to the isolated group B. DETAILED DESCRIPTION
[0043] The present invention will be described in detail below. The following embodiments are examples for explaining the present invention, but the purpose of the present invention is not limited to such embodiments. The present invention can be implemented in various forms within the scope of the present invention.
[0044] In addition, all documents and public publications, patent publications, and other patent documents cited in this specification are incorporated into this specification as reference. In addition, this specification includes the contents described in the specification and drawings of the Japanese patent application (Japanese Patent Application No. 2018-144512) filed on July 31, 2018, which is the basis for the priority claim of this application.
[0045] 1. Stevia plant with high sweetness content
[0046] In one aspect, the present invention provides a stevia plant containing a high amount of sweet ingredients (hereinafter sometimes referred to as "the plant of the present invention") having a mutation in a genome portion corresponding to sequence number 1. The base sequence represented by sequence number 1 is as follows.
[0047] [Table 1]
[0048] Table 1 Base sequence represented by sequence number 1
[0049]
[0050] The plant of the present invention is a species derived from a wild stevia plant, but has a gene mutation that increases the sweet component content (hereinafter sometimes referred to as "the mutation of the present invention").
[0051] “Having a mutation in the portion of the genome corresponding to SEQ ID NO. 1” means that there is a mutation in the portion consisting of the base sequence of SEQ ID NO. 1, or in the portion consisting of the base sequence substantially identical to SEQ ID NO. 1, in the genome of the Stevia plant. The base sequence substantially identical to SEQ ID NO. 1 refers to, for example, a base sequence having a sequence identity of 60% or more, 70% or more, 75% or more, 80% or more, 81% or more, 82% or more, 83% or more, 84% or more, 85% or more, 86% or more, 87% or more, 88% or more, 89% or more, 90% or more, 91% or more, 92% or more, 93% or more, 94% or more, 95% or more, 96% or more, 97% or more, 98% or more, 98.1% or more, 98.4% or more, 98.7% or more, 99% or more, 99.2% or more, 99.5% or more, or 99.8% or more with respect to the base sequence of SEQ ID NO. 1. In one embodiment, the genome portion corresponding to sequence number 1 contains a portion of the stevia plant genome amplified by the following forward primer and reverse primer: a forward primer that hybridizes with a portion 15 to 25 bases long from the 5' end of sequence number 1, and a reverse primer that hybridizes with a complementary sequence of a portion 15 to 25 bases long from the 3' end of sequence number 1. In a specific embodiment, the genome portion corresponding to sequence number 1 contains a portion of the stevia plant genome amplified by the following forward primer and reverse primer: a forward primer having a base sequence selected from sequence numbers 2 to 8, and a reverse primer having a base sequence selected from sequence numbers 9 to 15.
[0052] "Having a mutation in a genome portion" means that one or more bases are different from the main base sequence of a specified genome portion of the Stevia plant (e.g., SEQ ID NO. 1). Mutations include deletions, substitutions, and / or additions of nucleotides. In addition, mutations may be located in the coding region or non-coding region of a gene. When a mutation is located in a coding region, the mutation may or may not be accompanied by an amino acid mutation.
[0053] In one embodiment, the mutation includes a mutation at the following site in the genome of the Stevia plant: the site corresponding to position 11 of SEQ ID NO: 16, the site corresponding to position 21 of SEQ ID NO: 17, the site corresponding to position 31 of SEQ ID NO: 18, the site corresponding to position 41 of SEQ ID NO: 19, or the site corresponding to position 49 of SEQ ID NO: 1. The genome of the Stevia plant may have a portion consisting of a base sequence identical to SEQ ID NO: 16, 17, 18, 19, or 1, or may have a portion consisting of a base sequence corresponding to SEQ ID NO: 16, 17, 18, 19, or 1. In the former case, the mutation is present at the nucleotide at position 11, 21, 31, 41, or 49 from the 5' end of the portion consisting of a base sequence identical to SEQ ID NO: 16, 17, 18, 19, or 1 in the genome of the Stevia plant. On the other hand, in the latter case, since the genome of the Stevia plant body does not have a portion consisting of the same base sequence as SEQ ID NO: 16, 17, 18, 19 or 1, the mutation does not necessarily exist at position 11, 21, 31, 41 or 49 from the 5' end of the portion corresponding to SEQ ID NO: 16, 17, 18, 19 or 1, but the site corresponding to position 11, 21, 31, 41 or 49 of SEQ ID NO: 16, 17, 18, 19 or 1 in the genome of the Stevia plant can be determined by taking into account the base sequences before and after position 11, 21, 31, 41 or 49 of SEQ ID NO: 16, 17, 18, 19 or 1, etc. For example, by comparing the base sequence of the portion corresponding to sequence number 16, 17, 18, 19 or 1 in the genome of the Stevia plant with the base sequence of sequence number 16, 17, 18, 19 or 1, the site at position 11, 21, 31, 41, or 49 in the genome of the Stevia plant corresponding to sequence number 16, 17, 18, 19 or 1 can be determined.
[0054] In a specific embodiment, the mutation is a substitution of a nucleotide at the following site in the genome of the Stevia plant: the site corresponding to position 11 of SEQ ID NO: 16, the site corresponding to position 21 of SEQ ID NO: 17, the site corresponding to position 31 of SEQ ID NO: 18, the site corresponding to position 41 of SEQ ID NO: 19, or the site corresponding to position 49 of SEQ ID NO: 1. In a more specific embodiment, the mutation is a substitution from C (cytosine) to A (adenine) at the following site in the genome of the Stevia plant: the site corresponding to position 11 of SEQ ID NO: 16, the site corresponding to position 21 of SEQ ID NO: 17, the site corresponding to position 31 of SEQ ID NO: 18, the site corresponding to position 41 of SEQ ID NO: 19, or the site corresponding to position 49 of SEQ ID NO: 1 (hereinafter, this mutation may be referred to as "C49A"). The sequence in which position 49 of SEQ ID NO: 1 is substituted from C to A is shown in SEQ ID NO: 20.
[0055] The plant of the present invention is a type with a high sweet component content. A stevia plant with a high sweet component content refers to a stevia plant with a high sweet component content compared to a stevia plant that does not have the mutation of the present invention. High sweet component content means the following meanings: for example, in a segregating population obtained by mating two individual stevia plants, at least one of which is a heterozygous stevia plant having the mutation of the present invention, the average or median content of sweet components in the population of plants of the present invention (i.e., stevia plants having the mutation of the present invention) is higher than the average or median content of sweet components in the population of stevia plants that do not have the mutation of the present invention, and / or the plant of the present invention has a sweet component content that is higher than the average value of all individuals in the segregating population. In some embodiments, the average value of the sweet component content in a population of plants of the present invention belonging to the aforementioned isolated population is about 25% or more, about 50% or more, about 70% or more, about 80% or more, about 90% or more, about 100% or more, about 110% or more, about 120% or more, about 125% or more, about 130% or more, about 140% or more, about 150% or more, about 160% or more, about 170% or more, about 180% or more, about 190% or more, or about 195% or more higher than the average value of the sweet component content in a population of Stevia plants that do not have the mutation of the present invention and belong to the same isolated population. In addition, in some embodiments, the median content of sweet components in a population of plants of the present invention belonging to the aforementioned isolated population is about 25% or more, about 50% or more, about 75% or more, about 100% or more, about 125% or more, about 150% or more, about 160% or more, about 170% or more, about 180% or more, about 190% or more, about 195% or more, about 200% or more, or about 210% or more higher than the median content of sweet components in a population of Stevia plants that do not have the mutation of the present invention and belong to the same isolated population.
[0056] As the sweetening component, there is no particular limitation as long as it is a sweetening component contained in the stevia plant, and examples thereof include one or more steviol glycosides or a combination thereof. Examples of steviol glycosides include rebaudioside A, rebaudioside B, rebaudioside C, rebaudioside D, rebaudioside E, rebaudioside F, rebaudioside I, rebaudioside J, rebaudioside K, rebaudioside N, rebaudioside M, rebaudioside O, rebaudioside Q, rebaudioside R, dulcoside A, rubusoside, steviol, stevioside, stevioside, stevioside, and the like. In some embodiments, the sweet component is composed of one or more components selected from the group consisting of rebaudioside A, rebaudioside B, rebaudioside C, rebaudioside D, rebaudioside E, rebaudioside F, rebaudioside I, rebaudioside J, rebaudioside K, rebaudioside N, rebaudioside M, rebaudioside O, rebaudioside Q, rebaudioside R, dulcoside A, rubusoside, steviol, stevioside, steviolbioside, and stevioside. In a specific embodiment, the sweet component includes rebaudioside A, rebaudioside B, rebaudioside C, rebaudioside D, rebaudioside F, rebaudioside N, rebaudioside M, and rebaudioside O or consists of steviol glycosides thereof.
[0057] The stevia plant of the present invention is a species derived from a wild stevia plant, but has the aforementioned mutation in the gene that increases the content of sweet components. The mutation of the gene can be produced by a gene recombination method or a non-gene recombination method. In addition, the stevia plant of the present invention can have the aforementioned gene mutation in a heterozygous or homozygous form.
[0058] The aforementioned gene mutation can be detected by the following methods: PCR method, TaqMan PCR method, sequencing method, microarray method, Invader method, TILLING method, RAD (random amplified polymorphic DNA) method, restriction enzyme fragment length polymorphism (RFLP) method, PCR-SSCP method, AFLP (amplified fragment length polymorphism) method, SSLP (simple sequence length polymorphism) method, CAPS (cleaved amplified polymorphic sequence) method, dCAPS (derived cleaved amplified polymorphic sequence) method, allele-specific oligonucleotide (ASO) method, ARMS method, denaturing gradient gel electrophoresis (DGGE) method, CCM (chemical cleavage of mismatch) method, DOL method, MALDI-TOF / MS method, TDI method, padlock probe method, molecular beacon method, DASH (dynamic allele The detection method includes, but is not limited to, the specific hybridization method, UCAN method, ECA method, PINPOINT method, PROBE (primer oligo base extension) method, VSET (very short extension) method, Survivor assay, Sniper assay, Luminex assay, GOOD method, LCx method, SNaPshot method, Mass ARRAY method, pyrosequencing method, SNP-IT method, melting curve analysis method, etc. The detection method is described later in detail.
[0059] In this specification, as an example of "non-genetic recombination method", a method of inducing gene mutation of host cells (or host plants) without introducing foreign genes can be cited. As such a method, a method using a plant cell mutagen can be cited. As such a mutagen, ethyl methanesulfonate (EMS) and sodium azide can be cited. For example, plant cells can be treated with EMS at concentrations such as 0.1%, 0.2%, 0.3%, 0.4%, 0.5%, 0.6%, 0.7%, 0.8%, 0.9%, 1.0%. The treatment time is about 1 hour to about 48 hours, about 2 hours to about 36 hours, about 3 hours to about 30 hours, about 4 hours to about 28 hours, about 5 hours to about 26 hours, about 6 hours to about 24 hours. The treatment step itself is well known and can be carried out by soaking the hydrated seeds that have undergone the hydration process in a treatment solution containing a mutagen at the above concentration for the above treatment time.
[0060] As other examples of non-genetic recombination methods, there are methods of irradiating plant cells with radiation and light such as X-rays, gamma rays, and ultraviolet rays. In the case of ultraviolet irradiation, the cells are irradiated with an appropriate ultraviolet irradiation amount (ultraviolet lamp intensity, distance, time), and after culturing them in a selective medium, cells, callus tissues, and plants having target traits can be selected. At this time, the irradiation intensity can be 0.01-100Gr, 0.03-75Gr, 0.05-50Gr, 0.07-25Gr, 0.09-20Gr, 0.1-15Gr, 0.1-10Gr, 0.5-10Gr, 1-10Gr, the irradiation distance can be 1cm-200m, 5cm-100m, 7cm-75m, 9cm-50m, 10cm-30m, 10cm-20m, 10cm-10m, and the irradiation time can be 1 minute to 2 years, 2 minutes to 1 year, 3 minutes to 0.5 years, 4 minutes to 1 month, 5 minutes to 2 weeks, and 10 minutes to 1 week. The irradiation intensity, distance and time vary depending on the type of radiation and light and the situation set as the irradiation object (cell, callus, plant body), and can be appropriately adjusted by those skilled in the art.
[0061] In addition, methods such as cell fusion, anther culture (haploid breeding), and distant hybridization (haploid breeding) are already known.
[0062] Generally speaking, since plant cells may be accompanied by mutations during culture, it is preferable to return them to individual plants in order to maintain more stable traits.
[0063] Plants obtained by using non-genetically modified stevia plants as hosts and then performing genetic recombination (for example, plants obtained by performing genetic recombination using the plants of the present invention as hosts and further adding other traits) are also within the scope of the present invention.
[0064] The sweet component can be extracted in the form of an extract by reacting the fresh leaves or dried leaves of the plant of the present invention with an appropriate solvent (an aqueous solvent such as water or an organic solvent such as ethanol, ether and acetone). The extraction conditions, etc. can refer to the method described in Japanese Patent Publication No. 2012-504552 and the method described in the embodiments described below. Dried leaves refer to fresh leaves that are dried to reduce the water content to less than 10% by weight, less than 7% by weight, less than 5% by weight, less than 4% by weight, less than 3% by weight, less than 2% by weight, or less than 1% by weight. Preferably, the water content of the dried leaves of the plant of the present invention is 3 to 4% by weight.
[0065] Furthermore, for the extract obtained in this way, the sweet components can be purified by adopting the following well-known methods: ethyl acetate or other organic solvent: water gradient, high performance liquid chromatography (High Performance Liquid Chromatography: HPLC), gas chromatography, time-of-flight mass spectrometry (Time-of-Flight mass spectrometry: TOF-MS), ultra-high performance liquid chromatography (Ultra (High) Performance Liquid chromatography: UPLC), etc.
[0066] The sweet component content of the present invention can be measured by the method described in Japanese Patent Publication No. 2012-504552 and the method described in the Examples described below. Specifically, for example, the sweet component content can be measured by sampling fresh leaves from the stevia plant of the present invention and performing LC / MS-MS.
[0067] The plant body of the present invention is not only a whole plant body, but also can include plant organs (such as leaves, petals, stems, roots, seeds, etc.), plant tissues (such as epidermis, phloem, parenchyma, xylem, vascular bundle, palisade tissue, spongy tissue, etc.) or various forms of plant cells (such as suspension culture cells), protoplasts, leaf slices, callus tissue, etc.
[0068] In addition, the plant of the present invention may also include tissue culture or plant culture cells. Because by culturing such tissue culture or plant culture cells, the plant can be regenerated. Examples of the tissue culture or plant culture cells of the plant of the present invention include embryos, meristem cells, pollen, leaves, roots, root tips, petals, protoplasts, leaf sections, and callus tissue, but are not limited thereto.
[0069] In addition to the mutation of the present invention, the plant of the present invention may include other mutations, for example, a mutation that is positive for at least one dCAPS marker selected from WRKY-02-XbaI, WRKY-08-KpnI, WRKY-09-AflII, WRKY-14, and WD40-01-PvuI. Plants that are positive for these markers have a higher content of RebM than plants that are negative for these markers (hereinafter, such mutations may also be referred to as "high RebM-containing mutations").
[0070] The WRKY-02-XbaI positive result means that when the genomic DNA of the candidate plant is PCR-amplified using the forward primer having the base sequence shown in SEQ ID NO: 21 and the reverse primer having the base sequence shown in SEQ ID NO: 22, only an amplified band of about 383 bp in length (about 383 bp in length: for example, SEQ ID NO: 23 or 24) is obtained even when the obtained PCR product (about 383 bp in length: for example, SEQ ID NO: 23 or 24) is treated with the XbaI restriction enzyme. On the other hand, when the above PCR product is treated with the XbaI restriction enzyme and a restriction enzyme treatment product of about 344 bp (for example, SEQ ID NO: 25) is generated, the candidate plant is considered to be WRKY-02-XbaI negative.
[0071] The WRKY-08-KpnI positive result means that when the genomic DNA of the candidate plant is PCR amplified using the forward primer having the base sequence shown in SEQ ID NO: 26 and the reverse primer shown in SEQ ID NO: 27, even if the obtained PCR product (297 bp long) (e.g., SEQ ID NO: 28 or 29) is treated with the KpnI restriction enzyme, only an amplified band of about 297 bp in length (e.g., SEQ ID NO: 28 or 29) is obtained. On the contrary, when a restriction enzyme treatment product of about 258 bp (e.g., SEQ ID NO: 30) is produced, the candidate plant is considered to be WRKY-08-KpnI negative.
[0072] The WRKY-09-AflII positive result means that when the genomic DNA of the candidate plant is PCR-amplified using the forward primer having the base sequence shown in SEQ ID NO: 31 and the reverse primer shown in SEQ ID NO: 32, even if the obtained PCR product (about 390 bp in length) (for example, SEQ ID NO: 33 or 34) is treated with the AflII restriction enzyme, only an amplified band of about 390 bp in length (for example, SEQ ID NO: 33 or 34) is obtained. On the contrary, when a restriction enzyme-treated product of about 347 bp (for example, SEQ ID NO: 35) is produced, the candidate plant is considered to be WRKY-09-AflII negative.
[0073] Positive for WRKY-14 means that when the genomic DNA of the candidate plant is PCR amplified using a forward primer having the base sequence shown in sequence number 36 and a reverse primer shown in sequence number 37, only a PCR product of about 140 bp (for example, sequence number 38) is generated, and when PCR products of 140 bp (for example, sequence number 38) and 158 bp (for example, sequence number 39) are generated, the candidate plant is negative.
[0074] The WD40-01-PvuI positive result means that when the genomic DNA of the candidate plant is PCR-amplified using the forward primer having the base sequence shown in SEQ ID NO: 40 and the reverse primer shown in SEQ ID NO: 41, even if the obtained PCR product (about 288 bp in length) (for example, SEQ ID NO: 42 or 43) is treated with the PvuI restriction enzyme, only an amplified band of about 288 bp in length (for example, SEQ ID NO: 42 or 43) is obtained. On the other hand, when a restriction enzyme-treated product of about 240 bp (for example, SEQ ID NO: 44) is generated, the candidate plant is considered to be WD40-01-PvuI negative.
[0075] With respect to the above-mentioned bp length, "about" means ±5 bp. Restriction enzyme treatment can be carried out according to the conditions recommended by the vendors of the various restriction enzymes used.
[0076] The plant of the present invention may have, in addition to the above mutation and / or dCAPS marker-positive genetic characteristics, a mutation as shown in SEQ ID NO: 45, i.e., a mutation from A of the wild type to T at base sequence 60 corresponding to the base sequence of the wild type allele (SEQ ID NO: 46) (Patent Document 4). Plants having this mutation have a higher RebC content than plants not having this mutation (hereinafter sometimes referred to as "high RebC content mutation").
[0077] Since plants having the mutation of the present invention tend to have increased contents of all sweet components, by combining them with other mutations (e.g., high RebM-containing mutations and / or high RebC-containing mutations), the effects of these other mutations can be enhanced.
[0078] 2. Plant cultivation method of the present invention
[0079] In another embodiment, the present invention provides a method for growing a stevia plant containing a high amount of sweet ingredients (hereinafter referred to as "the growing method of the present invention"), comprising the step of hybridizing the stevia plant of the present invention with a second stevia plant.
[0080] The "stevia plant with high sweetness component content" cultivated by this method has the same phenotype and genetic properties as the plant of the present invention.
[0081] Specifically, the phenotype of the plant cultivated by the cultivation method of the present invention is the phenotype of the sweet component high content type described in the item of the plant of the present invention. The genetic performance of the plant cultivated by the cultivation method of the present invention has the mutation of the present invention. The plant cultivated by the cultivation method of the present invention may have the aforementioned mutation in a heterozygous or homozygous form. The detection methods of these mutations are as described above and below.
[0082] In the breeding method of the present invention, "hybridization" refers to obtaining a daughter plant (a plant bred by the breeding method of the present invention) by mating the plant of the present invention with a second plant. Backcrossing is preferred as a hybridization method. "Backcrossing" is a method of further hybridizing the daughter plant produced between the plant of the present invention and the second plant with the plant of the present invention (i.e., a plant having a gene mutation of the present invention) to breed a homozygous plant of the gene mutation of the present invention. When the second plant used in the breeding method of the present invention has the same phenotype and genetic properties as the plant of the present invention, it becomes a substantial backcross. The gene mutation of the present invention is inherited according to Mendel's law, and at the same time, the phenotype associated with the gene mutation, i.e., the phenotype with high sweet component content, is also inherited according to Mendel's law.
[0083] Alternatively, the plant of the present invention can be grown by self-pollination. Self-pollination can be performed by self-pollinating the pollen of the stamen of the plant of the present invention to the pistil of the plant of the present invention.
[0084] Since the plant grown by the breeding method of the present invention has the same phenotype and genetic properties as the plant of the present invention, a stevia plant high in sweetness components can be grown by further hybridizing the plant grown by the breeding method of the present invention with a third stevia plant.
[0085] As another embodiment, the plant of the present invention can be cultivated by culturing the tissue culture or plant culture cells described above to regenerate the plant. The culture conditions are the same as those for culturing tissue culture or plant culture cells of wild-type stevia plants, which are known (Protocols for In Vitro cultures and secondary metabolite analysis of aromatic and medicinal plants, Method in molecular biology, vo. 1391, pp113-123.).
[0086] As another embodiment, the plant of the present invention can be cultivated by introducing a mutation from C to A at the site corresponding to position 49 of SEQ ID NO: 1 in the genome of the Stevia plant. The introduction of the mutation can be carried out by a genetic recombination method or a non-genetic recombination method. The non-genetic recombination method includes the mutagenesis treatment described in the section of the plant of the present invention, such as treatment with a mutagen and treatment with radiation or light.
[0087] 3. Plant screening method of the present invention
[0088] The plant of the present invention can be screened by detecting the mutation of the present invention from the tissue of the test plant. Here, "screening" means to distinguish the plant of the present invention from other plants and then select the plant of the present invention.
[0089] Therefore, in another aspect, the present invention provides a method for screening a stevia plant body high in sweet components (hereinafter referred to as "the screening method of the present invention"), comprising the step of detecting a mutation in the portion corresponding to sequence number 1 from the genome of the test stevia plant body. The "mutation in the portion corresponding to sequence number 1" (mutation of the present invention) and the "stevia plant body high in sweet components" are as described above for the plant body of the present invention.
[0090] Specific examples of the method for detecting a mutation of the present invention include PCR method, TaqMan PCR method, sequencing method, microarray method, Invader method, TILLING method, RAD method, RFLP method, PCR-SSCP method, AFLP method, SSLP method, CAPS method, dCAPS method, ASO method, ARMS method, DGGE method, CCM method, DOL method, MALDI-TOF / MS method, TDI method, padlock probe method, molecular beacon method, DASH method, UCAN method, ECA method, PINPOINT method, PROBE method, VSET method, Survivor assay, Sniperassay, Luminex assay, GOOD method, LCx method, SNaPshot method, Mass ARRAY method, pyrosequencing method, SNP-IT method, melting curve analysis method, etc., but are not limited thereto.
[0091] In the case of PCR, it is preferred to prepare primers whose 3' end portion has a sequence complementary to the mutation site of the present invention. When using primers designed in this way, when the sample used as the template has a mutation, the polymerase extension reaction proceeds because the primers completely hybridize with the template; when the template does not have the mutation of the present invention, the extension reaction does not occur because the nucleotides at the 3' end of the primers and the template are mismatched. Therefore, when using such primers for PCR amplification and analyzing the amplification product by agarose gel electrophoresis, etc., as long as an amplification product of a specified size can be confirmed, it can be determined that the template used as the sample has a mutation, and when the amplification product does not exist, it can be determined that the template has no mutation.
[0092] Alternatively, the gene mutation of the present invention can be detected by making the mutation of the present invention not overlap with the primer sequence, designing the primer sequence so that the gene mutation of the present invention can be amplified by PCR, and sequencing the base sequence of the amplified nucleotide fragment.
[0093] For information on PCR and agarose gel electrophoresis, please refer to the following literature: Sambrook, Fritsch and Maniatis, "Molecular Cloning: A Laboratory Manual" 2nd Edition (1989), Cold Spring Harbor Laboratory Press.
[0094] The TaqMan PCR method is a method that utilizes a fluorescently labeled allele-specific oligomer and a Taq DNA polymerase to cause a PCR reaction (Livak, KJ Genet. Anal. 14, 143 (1999); Morris T. et al., J. Clin. Microbiol. 34, 2933 (1996)).
[0095] The sequencing method is a method of analyzing the presence of mutation by amplifying the region containing the mutation by PCR and sequencing the DNA sequence using a dye terminator or the like (Sambrook, Fritsch and Maniatis, "Molecular Cloning: A Laboratory Manual" 2nd Edition (1989), Cold Spring Harbor Laboratory Press).
[0096] DNA microarray is formed by fixing one end of a nucleotide probe on a support in an array, including DNA chips, gene chips, microchips, bead arrays, etc. By using a probe containing a sequence complementary to the gene mutation of the present invention, the presence or absence of the gene mutation of the present invention can be comprehensively detected. As a DNA microarray test such as a DNA chip, the GeneChip test (Affymetrix; see U.S. Patent No. 6,045,996, U.S. Patent No. 5,925,525 and U.S. Patent No. 5,858,659) can be cited. GeneChip technology is a technology that utilizes a miniaturized high-density microarray of oligonucleotide probes attached to a chip.
[0097] The Invader method is a method that combines the hybridization of two reporter gene probes and one Invader probe with template DNA and DNA cleavage caused by the Cleavase enzyme (Livak, KJ Biomol. Eng. 14, 143-149 (1999); Morris T. et al., J. Clin. Microbiol. 34, 2933 (1996); Lyamichev, V. et al., Science, 260, 778-783 (1993) etc.), wherein the reporter gene probe and the Invader probe are specific to each allele of a gene mutation such as SNP; and the Cleavase enzyme has a special endonuclease activity such as recognizing DNA structure and performing cleavage.
[0098] The TILLING (Targeting Induced Local Lesions IN Genomes) method is a screening method using PCR amplification and CEL I nuclease treatment, wherein PCR amplification amplifies mutation mismatches in the genome of the induced mutant population.
[0099] In one embodiment, the mutation of the present invention can be detected by the dCAPS method using the following primer pair and restriction enzyme.
[0100] Primer pairs:
[0101] A primer pair comprising the following forward primer and reverse primer: the forward primer comprises a sequence selected from sequence numbers 47 to 70 at the 3' end and any continuous sequence (e.g., a continuous sequence of any length) arbitrarily selected and added to the 5' end of the aforementioned sequence and extending from position 28 of sequence number 1 to the 5' end; the reverse primer comprises a sequence complementary to any continuous sequence of more than 20 bases located from position 50 of sequence number 1 to the 3' end (e.g., sequence numbers 15, 71). The primer sequence can be optimized within the range that satisfies the above conditions. For optimization of primer design, see, for example, Sambrook and Russell, "Molecular Cloning: A Laboratory Manual" 3rd Edition (2001), Cold Spring Harbor Laboratory Press, etc. In addition, each of the above primers can be 15 to 50 bases long, 18 to 48 bases long, 20 to 45 bases long, 30 to 65 bases long, etc.
[0102] Restriction enzymes:
[0103] The restriction enzymes corresponding to SEQ ID NOs: 47 to 70 are shown below. In the following sequences, "R" represents A or G, and "Y" represents C or T.
[0104] [Table 2]
[0105] Table 2 Sequences contained in forward primers and corresponding restriction enzymes
[0106] The sequence contained in the forward primer Restriction enzymes TTCAGGTAATAAAAGGCCTT (serial number 47) D D TTCAGGTAATAAAAGGCACT (serial number 48) MaeI / SpeI TTCAGGTAATAAAAGGCTTA (serial number 49) AflII / MseI TTCAGGTAATAAAAGGCTTG (serial number 50) Bc83I TTCAGGTAATAAAAGGCCTC (serial number 51) BseMII TTCAGGTAATAAAAGGCACG (serial number 52) BnI TTCAGGTAATAAAAGTCATG (serial number 53) BspHI / Hpy178III TTCAGGTAATAAAAGGCTRT (serial number 54) S i TTCAGGTAATAAAAGGCTTR (serial number 55) SmI TTCAGGTAATAAAAGGCAGC (serial number 56) EcoP15I TTCAGGTAATAAAAGGCYCG (serial number 57) AvaI TTCAGGTAATAAAAGTGATC (serial number 58) BclI TTCAGGTAATAAAAGGGAGG (serial number 59) BsE TTCAGGTAATAAAAGGCTGC (serial number 60) CviRI / PstI TTCAGGTAATAAAAGGAACC (serial number 61) DrdII TTCAGGTAATAAAAGGCTGA (serial number 62) Eco57I TTCAGGTAATAAAAGGCTGG (serial number 63) G JZ TTCAGGTAATAAAAGGGGTG (serial number 64) HkDJ TTCAGGTAATAAAAGGTCTG (serial number 65) Hpy188I TTCAGGTAATAAAAGGGAAG (serial number 66) MboII TTCAGGTAATAAAAGGTCGT (serial number 67) Pfl1108I TTCAGGTAATAAAAGTTATA (serial number 68) PsI TTCAGGTAATAAAAGGCTCG (serial number 69) TaqI / XhoI TTCAGGCGATAAAAGGCGTT (serial number 70) StySKI
[0107] In a specific embodiment, the mutation of the present invention can be detected by the dCAPS method using the following primer pair and restriction enzyme.
[0108] [Table 3]
[0109] Table 3 Combinations of primer pairs and restriction enzymes
[0110] Forward primer sequence Reverse primer sequence Restriction enzymes Serial Number 72 Sequence Number 15 D D Serial Number 73 Sequence Number 15 MaeI / SpeI Serial Number 74 Sequence Number 15 AflII / MseI Serial Number 75 Sequence Number 15 Bc83I Serial Number 76 Sequence Number 15 BseMII Serial Number 77 Sequence Number 15 BnI Serial Number 78 Sequence Number 15 BspHI / Hpy178III Serial Number 79 Sequence Number 15 S i Serial Number 80 Sequence Number 15 SmI Serial Number 81 Sequence Number 15 EcoP15I Serial Number 82 Sequence Number 15 AvaI Serial Number 83 Sequence Number 15 BclI Serial Number 84 Sequence Number 15 BsE Serial Number 85 Sequence Number 15 CviRI / PstI Serial Number 86 Sequence Number 15 DrdII Serial Number 87 Sequence Number 15 Eco57I Serial Number 88 Sequence Number 15 G JZ Serial Number 89 Sequence Number 15 HkDJ Serial Number 90 Sequence Number 15 Hpy188I Serial Number 91 Sequence Number 15 MboII Serial Number 92 Sequence Number 15 Pfl1108I Serial Number 93 Sequence Number 15 PsI Serial Number 94 Sequence Number 15 TaqI / XhoI Serial Number 95 Sequence Number 15 StySKI
[0111] The screening method of the present invention may further include a step of measuring the content of sweet components in the test stevia plant tissue in which the mutation has been detected. The sweet component content is determined as described in the item of the plant body of the present invention. In addition, in this method, the screening method of the present invention may also be applied to the daughter plants obtained by selecting individuals with high sweet component content from the test stevia plant bodies in which the mutation has been detected and mating them with other stevia plant bodies. Thus, the screening method of the present invention may include one or more of the following steps.
[0112] (i) a step of detecting a mutation in a portion corresponding to SEQ ID NO: 1 from the genome of a test Stevia plant,
[0113] (ii) a step of measuring the sweet component content of the test stevia plant tissue in which the mutation has been detected,
[0114] (iii) a step of selecting a stevia plant having a high sweet component content from among the stevia plants in which the mutation has been detected,
[0115] (iv) a step of mating the selected individual with a high sweet component content with other stevia plants,
[0116] (v) a step of detecting a mutation in the portion corresponding to SEQ ID NO: 1 from the genome of the daughter plant obtained by mating,
[0117] (vi) a step of measuring the sweet component content of the daughter plant tissue in which the mutation has been detected,
[0118] (vii) A step of selecting daughter plants having a high sweet component content from among the daughter plants in which the mutation has been detected.
[0119] For example, among the tested stevia plants in which mutations have been detected, the selected individuals with high sweetness component content may be individuals with the following degree of superiority correlated with the sweetness component content, etc.: superiority of 50%, superiority of 40%, superiority of 30%, superiority of 20%, superiority of 10%, superiority of 5%, superiority of 4%, superiority of 3%, superiority of 2% or superiority of 1%. In addition, other stevia plants for mating may or may not contain the mutation of the present invention. In the above method, steps (iv) to (vii) may be repeated multiple times. In this way, stevia plants with higher sweetness component content can be screened out.
[0120] In the screening method of the present invention, the stevia plant to be tested may be a natural plant or a non-genetically modified plant. The non-genetically modified plant is as described in the section of the plant of the present invention.
[0121] In the screening method of the present invention, the test stevia plant may also include stevia plants that have been subjected to mutagenesis treatment and their progeny plants. The mutagenesis treatment includes treatment with a mutagen and treatment with radiation or light, as described in the plant section of the present invention.
[0122] In one embodiment, at least one of the mating parents of the tested stevia plant in the screening method of the present invention has the mutation of the present invention in a heterozygous form, and none of the mating parents of the tested stevia plant has the mutation of the present invention in a homozygous form. In this embodiment, the tested stevia plant belongs to a segregating population, which is produced by mating two individual stevia plants, at least one of which has the mutation of the present invention in a heterozygous form. In the development of more excellent varieties, such as varieties with higher sweet component content, sometimes a segregating population is obtained by mating individuals with high sweet component content with each other or mating individuals with high sweet component content with individuals showing other phenotypes, and then selecting individuals with high sweet component content from the segregating population, but it takes a lot of time, cost, and labor to quantify the sweet component content of all individuals in the segregating population. In contrast, the detection of genetic mutations can be carried out with less time, cost, and labor than the detection of sweet component content. In a segregating population produced by mating two individual stevia plants, at least one of which is a heterozygous stevia plant having the mutation of the present invention, the mutation of the present invention is included in individuals having a sweet component content above the average value, which can be experimentally confirmed (see Examples), and by detecting the mutation of the present invention, individuals having a sweet component content above the average value can be selected from the aforementioned segregating population. As a result, the number of individuals to be measured for the sweet component content can be greatly reduced, thereby improving the cost, speed, efficiency, success rate, etc. of breeding and development of stevia plants with high sweet component content.
[0123] The present invention provides a probe that can detect the presence or absence of a mutation of the present invention (hereinafter sometimes referred to as "the probe of the present invention"). The probe of the present invention may have a structure suitable for various detection methods of the mutation of the present invention. For example, the probe of the present invention may contain a base sequence that is complementary to a portion of a genome or transcript containing a mutation site of the present invention. As a non-limiting example of the probe, there can be cited a probe that specifically hybridizes with a base sequence selected from sequence numbers 1, 16 to 20, and 99 to 102. Among these sequences, sequence numbers 20 and 99 to 102 are base sequences containing the mutation of the present invention, and sequence numbers 1 and 16 to 19 are base sequences that do not contain the mutation of the present invention. In a preferred embodiment, the probe that can detect the presence of the mutation of the present invention has the following hybridization conditions: it hybridizes with a base sequence selected from sequence numbers 20 and 99 to 102, but does not hybridize with a base sequence selected from sequence numbers 1 and 16 to 19. In a preferred embodiment, the probe capable of detecting the absence of the mutation of the present invention has the following hybridization conditions: hybridizes with the base sequence selected from SEQ ID NOs: 1 and 16 to 19, but does not hybridize with the base sequence selected from SEQ ID NOs: 20 and 99 to 102.
[0124] The presence of the mutation of the present invention can be detected by detecting the base sequence containing the mutation of the present invention and / or non-detecting the base sequence not containing the mutation of the present invention, and the absence of the mutation of the present invention can be detected by non-detecting the base sequence containing the mutation of the present invention and / or detecting the base sequence not containing the mutation of the present invention.
[0125] The probe of the present invention preferably has a label. Non-limiting examples of such labels include fluorescent labels, luminescent labels, radioactive labels, pigments, enzymes, quenching groups, and binding portions with detectable labels. In a specific embodiment, the probe of the present invention has a base sequence that specifically hybridizes with a base sequence selected from sequence numbers 1, 16 to 20, and 99 to 102 and a label.
[0126] The present invention also provides a primer pair and a kit, wherein the primer pair contains the aforementioned combination of a forward primer and a reverse primer, and the kit contains the aforementioned primer pair and a restriction enzyme corresponding thereto. The present invention further provides a kit containing a primer pair and the probe of the present invention, wherein the primer pair is a primer pair capable of obtaining a region containing a base sequence selected from sequence numbers 1, 16 to 20, and 99 to 102 by PCR amplification. These primer pairs and kits can be applied to aspects such as the detection of mutations of the present invention and the screening method of the present invention. In addition, these primer pairs and kits contain instructions for explanation related to the detection of mutations of the present invention and the screening method of the present invention, for example, instructions for use and media recording information related to the method of use, such as floppy disks, CDs, DVDs, Blu-ray discs, memory cards, USB memories, etc.
[0127] 4. Extracts derived from the plants of the present invention and products using the same
[0128] In another aspect of the present invention, a method for producing an extract containing stevia sweetness components (hereinafter referred to as "the method for producing the extract of the present invention") is provided, which includes the step of obtaining an extract from the plant of the present invention or the seeds or dried leaves of the plant. Further, a method for producing a stevia sweetness component (hereinafter referred to as "the method for producing a stevia sweetness component of the present invention") is provided, which includes the step of purifying the stevia sweetness components from the extract obtained by the method for producing an extract of the present invention. Since the stevia sweetness components include various steviol glycosides as described above, the method for producing a stevia sweetness component of the present invention includes a method for producing various steviol glycosides.
[0129] The extract containing the sweet taste component of stevia can be prepared by reacting the fresh or dried leaves of the plant of the present invention with an appropriate solvent (aqueous solvent such as water or organic solvent such as ethanol, ether and acetone). The extraction conditions can refer to the method described in Japanese Patent Application No. 2012-504552 and the method described in the Examples described below.
[0130] In addition, for the extract containing stevia sweet components, the stevia sweet components can be purified by adopting the following well-known methods: ethyl acetate and other organic solvents: water gradient, high performance liquid chromatography (High Performance Liquid Chromatography: HPLC), gas chromatography, time-of-flight mass spectrometry (Time-of-Flight mass spectrometry: TOF-MS), ultra-high performance liquid chromatography (Ultra (High) Performance Liquid chromatography: UPLC), etc.
[0131] The extract obtained by the method for producing an extract of the present invention (hereinafter referred to as "the extract of the present invention") is characterized in that it has a high content of sweet components compared to an extract obtained by the same method from a stevia plant that does not contain the mutation of the present invention. Here, "high content of sweet components" is as described in the item of the plant of the present invention.
[0132] The stevia sweetness component obtained by the extract of the present invention and / or the method for producing the stevia sweetness component of the present invention (hereinafter referred to as "the stevia sweetness component of the present invention") is mixed with other ingredients, thereby producing a new pharmaceutical product, flavor or food and drink with an increased content of stevia sweetness component. Therefore, in other aspects, the present invention provides a method for producing a pharmaceutical product, flavor or food and drink, which includes the step of mixing the extract of the present invention and / or the stevia sweetness component of the present invention with other ingredients. Furthermore, the present invention provides a new pharmaceutical product, flavor or food and drink, which is a product with an increased content of stevia sweetness component obtained by the aforementioned production method. Here, food and drink refers to beverages and foods. Therefore, in one embodiment, the present invention provides a new pharmaceutical product, flavor, beverage or food, and further provides a method for producing the pharmaceutical product, flavor, beverage or food.
[0133] 5. Base sequences involved in the plants of the present invention
[0134] In another aspect, the present invention provides a base sequence related to the stevia plant of the present invention. A specific embodiment of the base sequence related to the stevia plant having the mutation of the present invention comprises or consists of a base sequence selected from SEQ ID NOs: 20 and 99 to 102.
[0135] Example
[0136] Experimental examples and working examples related to the present invention are described below, but the present invention is not limited to these specific embodiments.
[0137] (1) Isolation of individuals with high sweetness content (M0 generation)
[0138] About 2000 (by weight) wild-type stevia seeds (commercial variety introduced in August 2014) were divided into three parts and treated with 0.1%, 0.2% or 0.3% ethyl methanesulfonate (EMS) respectively for genetic modification.
[0139] These EMS-treated seeds and untreated seeds were sown in the greenhouse of Suntory Research Center to obtain EMS-treated generation (M0 generation) seedlings. No difference in germination rate was found between the treatment concentrations.
[0140] An appropriate amount of fresh leaves were sampled from the EMS-treated generation (M0 generation) and untreated individuals, and the concentration of sweet components was quantified using LC / MS-MS (Shimadzu LCMS8050). Specifically, 0.25 g of fresh leaves were freeze-dried and 0.05 g of crushed dry matter was put into pure water. The extract was extracted by ultrasonic treatment for 20 minutes, and 0.33 ml of extract was obtained after centrifugation and filtration. The extract was analyzed by LC / MS-MS using LCMS8050 ion mode (Shimadzu LCMS8050) to quantify the concentrations of RebA, RebB, RebC, RebD, RebF, RebM, RebN and RebO, and the total was taken as the concentration of sweet components. The individual with a sweet component concentration of about 20% was taken as parent individual 1 (P1). In addition, an individual derived from another Stevia plant population and with a sweet component concentration of 5% in dry leaves was selected as parent individual 2 (P2).
[0141] (2) Isolation of individuals with high sweetness content (M1 generation) and genetic analysis
[0142] The first generation (M1 generation) seeds were collected and processed by mating parent individual 1 (P1) with parent individual 2 (P2), and sown in the greenhouse of Suntory Research Center to obtain M1 generation seedlings (segregating population of 1603 individuals). An appropriate amount of fresh leaves were sampled from the above M1 generation individuals, and the sweet components were quantified by LC / MS-MS (Shimadzu LCMS8050) in the same way as in (1) above. The results are shown in Figure 1 .
[0143] Genomic DNA was extracted from fresh leaves of the 30 individuals with the highest sweetness component content (sweetness component high-content individuals) and the 30 individuals with the lowest sweetness component content (sweetness component low-content individuals), and mutations that only exist in one of the two individual groups were investigated. Among the mutations detected by genomic analysis, 306 mutations with sufficient genomic information (sequence coverage of ×5 or more), discontinuous mutations, and no sequence insertions and deletions were studied to determine which individual each mutation exists in. As a result, it was clarified that the mutation from C to A (C49A) at position 49 of sequence number 1 exists in individuals with high sweetness component content, but not in individuals with low sweetness component content.
[0144] (3) Verification of the relationship between mutation C49A and sweet component content
[0145] Stevia plants with mutant C49A in a heterozygous form were mated with Stevia plants without mutant C49A to obtain two isolated groups (isolated group A (443 individuals) and isolated group B (446 individuals)). The presence of mutant C49A and the content of sweet components in each individual of the two isolated groups were investigated. The dCAPS method was used to investigate the presence of mutant C49A. Genomic DNA was extracted from each individual, PCR was performed using the following primers, and a restriction enzyme (SpeI) was added to the PCR product, and the enzyme reaction was carried out at 37°C. After restriction enzyme treatment, electrophoresis was performed using a microchip electrophoresis device LAbChip GX Touch HT (PerkinElmer), and the marker was identified based on the amplified band pattern after electrophoresis.
[0146] Forward primer: 5'-TTATTTAATGATCCAATGGAGGGGGTGATTCAGGTAATAAAAGGCACT-3' (SEQ ID NO: 71)
[0147] Reverse primer: 5'-TGAGGGTTCTCAATTGATTTCCGATTGG-3' (SEQ ID NO: 15)
[0148] The obtained PCR product of about 367 bp (eg, sequence number 96 or 97) was treated with SpeI restriction enzyme, and those that produced a restriction enzyme-treated product of about 321 bp (eg, sequence number 98) were considered positive for the mutation C49A.
[0149] The sweet component content was quantified in the same manner as in (1).
[0150] The distribution of sweet component content in mutation C49A positive individuals and negative individuals of each segregating population is shown in Figures 2-3 These results show that the sweet component content in mutation C49A-positive individuals is higher than the average value of the sweet component content of all the segregating groups.
[0151] In addition, the mean and median values of the sweet component contents in mutation C49A-positive and -negative individuals of each segregating group are summarized below.
[0152] [Table 4]
[0153] Table 4 Mean and median values of sweet component concentrations in dry leaves of each isolated population (%)
[0154] Sequence Listing <110> Suntory Holdings Co., Ltd. <120> Stevia plant with high sweetness content and screening method thereof <130> G2079WO <150> JP 2018-144512 <151> 2018-07-31 <160> 102 <170> PatentIn version 3.5 <210> 1 <211> 367 <212> DNA <213> Stevia <400> 1 ttatttaatg atccaatgga gggggtgatt caggtaataa aaggcattcg tatggaatat 60 accaaaacat tgcgattcgt tattagcatg gatctttcaa gtaataaact tatcggagaa 120 ataccagttg agttaactgc ccttcatgcc ttggtgagtc tcaatttgtc taataatcat 180 cttattggac acattccgaa tagcattgga aacatgaaag ctttaaattc tctagatttc 240 tcgagaaacg agttaaatgg gttgatccct ccaagcattg gagctttgaa ttttttgagt 300 catttaaatt tgtcaaacaa caacttatca ggaccaattc caatcggaaa tcaattgaga 360 accctca 367 <210> 2 <211> 14 <212> DNA <213> Stevia <400> 2 ttatttaatg atcc 14 <210> 3 <211> 15 <212> DNA <213> Stevia <400> 3 ttatttaatg atcca 15 <210> 4 <211> 16 <212> DNA <213> Stevia <400> 4 ttatttaatg atccaa 16 <210> 5 <211> 17 <212> DNA <213> Stevia <400> 5 ttatttaatg atccaat 17 <210> 6 <211> 18 <212> DNA <213> Stevia <400> 6 ttatttaatg atccaatg 18 <210> 7 <211> 19 <212> DNA <213> Stevia <400> 7 ttatttaatg atccaatgg 19 <210> 8 <211> 48 <212> DNA <213> Stevia <400> 8 ttatttaatg atccaatgga gggggtgatt caggtaataa aaggcatt 48 <210> 9 <211> 14 <212> DNA <213> Stevia <400> 9 tgagggttct caat 14 <210> 10 <211> 15 <212> DNA <213> Stevia <400> 10 tgagggttct caatt 15 <210> 11 <211> 16 <212> DNA <213> Stevia <400> 11 tgagggttct caattg 16 <210> 12 <211> 17 <212> DNA <213> Stevia <400> 12 tgagggttct caattga 17 <210> 13 <211> 18 <212> DNA <213> Stevia <400> 13 tgagggttct caattgat 18 <210> 14 <211> 19 <212> DNA <213> Stevia <400> 14 tgagggttct caattgatt 19 <210> 15 <211> 28 <212> DNA <213> Stevia <400> 15 tgagggttct caattgattt ccgattgg 28 <210> 16 <211> 21 <212> DNA <213> Stevia <400> 16 aaaaggcatt cgtatggaat a 21 <210> 17 <211> 41 <212> DNA <213> Stevia <400> 17 ttcaggtaat aaaaggcatt cgtatggaat ataccaaaac a 41 <210> 18 <211> 61 <212> DNA <213> Stevia <400> 18 gagggggtga ttcaggtaat aaaaggcatt cgtatggaat ataccaaaac attgcgattc 60 g 61 <210> 19 <211> 81 <212> DNA <213> Stevia <400> 19 tgatccaatg gagggggtga ttcaggtaat aaaaggcatt cgtatggaat ataccaaaac 60 attgcgattc gttattagca t 81 <210> 20 <211> 367 <212> DNA <213> Stevia <400> 20 ttatttaatg atccaatgga gggggtgatt caggtaataa aaggcattag tatggaatat 60 accaaaacat tgcgattcgt tattagcatg gatctttcaa gtaataaact tatcggagaa 120 ataccagttg agttaactgc ccttcatgcc ttggtgagtc tcaatttgtc taataatcat 180 cttattggac acattccgaa tagcattgga aacatgaaag ctttaaattc tctagatttc 240 tcgagaaacg agttaaatgg gttgatccct ccaagcattg gagctttgaa ttttttgagt 300 catttaaatt tgtcaaacaa caacttatca ggaccaattc caatcggaaa tcaattgaga 360 accctca 367 <210> 21 <211> 43 <212> DNA <213> Artificial sequence <220> <223> Synthetic DNA <400> 21 aaggttcttt atttttaaac ttatgttaat ttattgtatc tag 43 <210> 22 <211> 21 <212> DNA <213> Artificial sequence <220> <223> Synthetic DNA <400> 22 ccttatgtac acatgctaca c 21 <210> 23 <211> 383 <212> DNA <213> Artificial sequence <220> <223> PCR product <400> 23 aaggttcttt atttttaaac ttatgttaat ttattgtatc tagtagttaa tcaagagatg 60 ctctcttgga gaaattttat ggtcataaaa cctatatcaa agagatgctc tcttggtata 120 ttccatactt aaaatatcta ttttggaaaa aaagtgtagc atcttcctgc ttttagtagg 180 tgtcaatcat tattaaattt cacaaaaccg tgcaagaatc ccagtttccc tatagtttgt 240 atacgttcct gatctagtat tttacttatg tttcaaatca atccaatcat gcttgtgtcc 300 gaaaattaaa aaacaagggt attggatgcc ctgtaccact attattaact tttcagaaaa 360 acgtgtagca tgtgtacata agg 383 <210> 24 <211> 383 <212> DNA <213> Artificial sequence <220> <223> PCR product <400> 24 aaggttcttt atttttaaac ttatgttaat ttattgtatc tagaagttaa tcaagagatg 60 ctctcttgga gaaattttat ggtcataaaa cctatatcaa agagatgctc tcttggtata 120 ttccatactt aaaatatcta ttttggaaaa aaagtgtagc atcttcctgc ttttagtagg 180 tgtcaatcat tattaaattt cacaaaaccg tgcaagaatc ccagtttccc tatagtttgt 240 atacgttcct gatctagtat tttacttatg tttcaaatca gtccaatcat gcttgtgtcc 300 gaaaattaaa aaacaagggt attggatgcc ctgtaccact attattaact tttcagaaaa 360 acgtgtagca tgtgtacata agg 383 <210> 25 <211> 344 <212> DNA <213> Artificial sequence <220> <223> Digestive product <400> 25 ctagaagtta atcaagagat gctctcttgg agaaatttta tggtcataaa acctatatca 60 aagagatgct ctcttggtat attccatact taaaatatct attttggaaa aaaagtgtag 120 catcttcctg cttttagtag gtgtcaatca ttattaaatt tcacaaaacc gtgcaagaat 180 cccagtttcc ctatagtttg tatacgttcc tgatctagta ttttacttat gtttcaaatc 240 agtccaatca tgcttgtgtc cgaaaattaa aaaacaaggg tattggatgc cctgtaccac 300 tattattaac ttttcagaaa aacgtgtagc atgtgtacat aagg 344 <210> 26 <211> 39 <212> DNA <213> Artificial sequence <220> <223> Synthetic DNA <400> 26 taatcatcca aaccctaatc tcgccaaaca accgggtac 39 <210> 27 <211> 20 <212> DNA <213> Artificial sequence <220> <223> Synthetic DNA <400> 27 gaggaagaca ttggcaactc 20 <210> 28 <211> 297 <212> DNA <213> Artificial sequence <220> <223> PCR product <400> 28 taatcatcca aaccctaatc tcgccaaaca accgggtact gatccaaacc ctgaaatgag 60 cacaactctt gaacctgatc acgagaatga agagcacaaa catgttatga cacatgtaaa 120 cgatggtttt tgctacatga aaaccctaga agacgaaacc cgtttaactg taaatcttga 180 aaacacattc tttgatgaaa aacccctttc gtatccggat cttatggact tttctgcatc 240 gaaaacggac gaatacgact tctatgatga acttgaagag ctgccaatgt cttcctc 297 <210> 29 <211> 297 <212> DNA <213> Artificial sequence <220> <223> PCR product <400> 29 taatcatcca aaccctaatc tcgccaaaca accgggtacc gatccaaacc ctgaaatgag 60 cacaactctt gaacctgatc acgagaatga agagcacaaa catgttatga cacatgtaaa 120 cgatggtttt tgctacatga aaaccctaga agacgaaacc cgtttaagtg taaatcttga 180 aaacacattc tttgatgaag aacccctttc gtatccggat cttatggact tttctgcatc 240 gaaaaaggac gaatacgact tctatgatga acttgaagag ttgccaatgt cttcctc 297 <210> 30 <211> 258 <212> DNA <213> Artificial sequence <220> <223> Digestion products <400> 30 cgatccaaac cctgaaatga gcacaactct tgaacctgat cacgagaatg aagagcacaa 60 acatgttatg acacatgtaa acgatggttt ttgctacatg aaaaccctag aagacgaaac 120 ccgtttaagt gtaaatcttg aaaacacatt ctttgatgaa gaaccccttt cgtatccgga 180 tcttatggac ttttctgcat cgaaaaagga cgaatacgac ttctatgatg aacttgaaga 240 gttgccaatg tcttcctc 258 <210> 31 <211> 47 <212> DNA <213> Artificial sequence <220> <223> Synthetic DNA <400> 31 cgatggtttt tgctacatga aaaccctaga agacgaaacc cgcttaa 47 <210> 32 <211> twenty three <212> DNA <213> Artificial sequence <220> <223> Synthetic DNA <400> 32 accagcaata atccttgaat tag 23 <210> 33 <211> 390 <212> DNA <213> Artificial sequence <220> <223> PCR product <400> 33 cgatggtttt tgctacatga aaaccctaga agacgaaacc cgcttaactg taaatcttga 60 aaacacattc tttgatgaaa aacccctttc gtatccggat cttatggact tttctgcatc 120 gaaaacggac gaatacgact tctatgatga acttgaagag ctgccaatgt cttcctcatc 180 attcaaaagc ttcatgagaa gtaatttctt tgaggaaaga gttcttgttc aaccttattg 240 attaagaatt taagggaagc agattatata tgtaattaaa ttttggtatt tatactttga 300 acttaattaa taattataat aataatccca actagaggca cttagtggag attacttata 360 tataatacta attcaaggat tattgctggt 390 <210> 34 <211> 390 <212> DNA <213> Artificial sequence <220> <223> PCR product <400> 34 cgatggtttt tgctacatga aaaccctaga agacgaaacc cgcttaagtg taaatcttga 60 aaacacattc tttgatgaag aacccctttc gtatccggat cttatggact tttctgcatc 120 gaaaaaggac gaatacgact tctatgatga acttgaagag ttgccaatgt cttcctcatc 180 attcaaaagc ttcatgagaa gtaatttctt tgaggaaaga gttcttgttc aaccttattg 240 attaagaatt taagggaagc agattatata tgtaattaaa ttttggtatt tatactttga 300 acttaattaa taattataat aataatccca actagaggca cttagtggag attacttata 360 tataatacta attcaaggat tattgctggt 390 <210> 35 <211> 347 <212> DNA <213> Artificial sequence <220> <223> Digestive product <400> 35 ttaagtgtaa atcttgaaaa cacattcttt gatgaagaac ccctttcgta tccggatctt 60 atggactttt ctgcatcgaa aaaggacgaa tacgacttct atgatgaact tgaagagttg 120 ccaatgtctt cctcatcatt caaaagcttc atgagaagta atttctttga ggaaagagtt 180 cttgttcaac cttattgatt aagaatttaa gggaagcaga ttatatatgt aattaaattt 240 tggtatttat actttgaact taattaataa ttataataat aatcccaact agaggcactt 300 agtggagatt acttatatat aatactaatt caaggattat tgctggt 347 <210> 36 <211> 20 <212> DNA <213> Artificial sequence <220> <223> Synthetic DNA <400> 36 cgcaaacacg tatactaatc 20 <210> 37 <211> 20 <212> DNA <213> Artificial sequence <220> <223> Synthetic DNA <400> 37 tttagcatgg tatgtacaac 20 <210> 38 <211> 140 <212> DNA <213> Artificial sequence <220> <223> PCR products <400> 38 cgcaaacacg tatactaatc acgtaacata ttttttatattt ctaaattaaa atttgaatta 60 aagataacat aatatttatt tttagagtgt aacttctaaa aaatatcaac ctacgaaaaa 120 gttgtacata ccatgctaaa 140 <210> 39 <211> 158 <212> DNA <213> Artificial sequence <220> <223> PCR products <400> 39 cgcaaacacg tatactaatc acgtaacata ttttttatattt ctaaattaaa attttataac 60 aatatcatac ttgaattaaa gataacataa tatttatttt tagagtgtaa cttctaaaaa 120 atatcaacct acgaaaaagt tgtacatacc atgctaaa 158 <210> 40 <211> 49 <212> DNA <213> Artificial sequence <220> <223> Synthetic DNA <400> 40 atacaaaaac acaacccata tggtcaaatc aacccattca tgagcgatc 49 <210> 41 <211> twenty two <212> DNA <213> Artificial sequence <220> <223> Synthetic DNA <400> 41 cccttgtaaa tcccatatgt ag 22 <210> 42 <211> 288 <212> DNA <213> Artificial sequence <220> <223> PCR products <400> 42 atacaaaaac acaacccata tggtcaaatc aacccattca tgagcgatca ggtcaaattc 60 gctatctgag ctgatgcatt caactatttg gtctcttttt aacatttatt ttttttatta 120 ttttgaatgt agaaactttg gaactactca actggtaagt tcttgaagat gtataccggt 180 catgtaaaca aaacatattg tataactccg actttttctg taacaaatgg aaaatatatt 240 gttagtggtt cagaagatca ttgtgtctac atatgggatt tacaaggg 288 <210> 43 <211> 288 <212> DNA <213> Artificial sequence <220> <223> PCR product <400> 43 atacaaaaac acaacccata tggtcaaatc aacccattca tgagcgatcg ggtcaaattc 60 gctatctgag ctgatgcatt caactatttg gtctcttttt aacatttatt ttttttatta 120 ttttgaatgt agaaactttg gaactactca actggtaagt tcttgaagat gtataccggt 180 catgtaaaca aaacatattg tataactccg actttttctg taacaaatgg aaaatatatt 240 gttagtggtt cagaagatca ttgtgtctac atatgggatt tacaaggg 288 <210> 44 <211> 240 <212> DNA <213> Artificial sequence <220> <223> Digestive product <400> 44 cgggtcaaat tcgctatctg agctgatgca ttcaactatt tggtctcttt ttaacattta 60 ttttttttat tattttgaat gtagaaactt tggaactact caactggtaa gttcttgaag 120 atgtataccg gtcatgtaaa caaaacatat tgtataactc cgactttttc tgtaacaaat 180 ggaaaatata ttgttagtgg ttcagaagat cattgtgtct acatatggga tttacaaggg 240 <210> 45 <211> 60 <212> DNA <213> Stevia <400> 45 gagtaaaatc tataacgaca ctaaggtgga aaaagaatat gtaagccaat tcgtagactt 60 <210> 46 <211> 60 <212> DNA <213> Stevia <400> 46 gagtaaaatc tataacgaca ctaaggtgga aaaagaatat gtaagccaat tcgtagacta 60 <210> 47 <211> 20 <212> DNA <213> Artificial Sequence <220> <223> Synthetic DNA <400> 47 ttcaggtaat aaaaggcctt 20 <210> 48 <211> 20 <212> DNA <213> Artificial Sequence <220> <223> Synthetic DNA <400> 48 ttcaggtaat aaaaggcact 20 <210> 49 <211> 20 <212> DNA <213> Artificial sequence <220> <223> Synthetic DNA <400> 49 ttcaggtaat aaaaggctta 20 <210> 50 <211> 20 <212> DNA <213> Artificial sequence <220> <223> Synthetic DNA <400> 50 ttcaggtaat aaaaggcttg 20 <210> 51 <211> 20 <212> DNA <213> Artificial sequence <220> <223> Synthetic DNA <400> 51 ttcaggtaat aaaaggcctc 20 <210> 52 <211> 20 <212> DNA <213> Artificial sequence <220> <223> Synthetic DNA <400> 52 ttcaggtaat aaaaggcacg 20 <210> 53 <211> 20 <212> DNA <213> Artificial sequence <220> <223> Synthetic DNA <400> 53 ttcaggtaat aaaagtcatg 20 <210> 54 <211> 20 <212> DNA <213> Artificial sequence <220> <223> Synthetic DNA <400> 54 ttcaggtaat aaaaggctrt 20 <210> 55 <211> 20 <212> DNA <213> Artificial sequence <220> <223> Synthetic DNA <400> 55 ttcaggtaat aaaaggcttr 20 <210> 56 <211> 20 <212> DNA <213> Artificial sequence <220> <223> Synthetic DNA <400> 56 ttcaggtaat aaaaggcagc 20 <210> 57 <211> 20 <212> DNA <213> Artificial sequence <220> <223> Synthetic DNA <400> 57 ttcaggtaat aaaaggcycg 20 <210> 58 <211> 20 <212> DNA <213> Artificial sequence <220> <223> Synthetic DNA <400> 58 ttcaggtaat aaaagtgatc 20 <210> 59 <211> 20 <212> DNA <213> Artificial sequence <220> <223> Synthetic DNA <400> 59 ttcaggtaat aaaagggagg 20 <210> 60 <211> 20 <212> DNA <213> Artificial sequence <220> <223> Synthetic DNA <400> 60 ttcaggtaat aaaaggctgc 20 <210> 61 <211> 20 <212> DNA <213> Artificial sequence <220> <223> Synthetic DNA <400> 61 ttcaggtaat aaaaggaacc 20 <210> 62 <211> 20 <212> DNA <213> Artificial sequence <220> <223> Synthetic DNA <400> 62 ttcaggtaat aaaaggctga 20 <210> 63 <211> 20 <212> DNA <213> Artificial sequence <220> <223> Synthetic DNA <400> 63 ttcaggtaat aaaaggctgg 20 <210> 64 <211> 20 <212> DNA <213> Artificial sequence <220> <223> Synthetic DNA <400> 64 ttcaggtaat aaaaggggtg 20 <210> 65 <211> 20 <212> DNA <213> Artificial sequence <220> <223> Synthetic DNA <400> 65 ttcaggtaat aaaaggtctg 20 <210> 66 <211> 20 <212> DNA <213> Artificial sequence <220> <223> Synthetic DNA <400> 66 ttcaggtaat aaaagggaag 20 <210> 67 <211> 20 <212> DNA <213> Artificial sequence <220> <223> Synthetic DNA <400> 67 ttcaggtaat aaaaggtcgt 20 <210> 68 <211> 20 <212> DNA <213> Artificial sequence <220> <223> Synthetic DNA <400> 68 ttcaggtaat aaaagttata 20 <210> 69 <211> 20 <212> DNA <213> Artificial sequence <220> <223> Synthetic DNA <400> 69 ttcaggtaat aaaaggctcg 20 <210> 70 <211> 20 <212> DNA <213> Artificial sequence <220> <223> Synthetic DNA <400> 70 ttcaggcgat aaaaggcgtt 20 <210> 71 <211> 20 <212> DNA <213> Stevia <400> 71 tgttttggta tattccatac 20 <210> 72 <211> 48 <212> DNA <213> Artificial sequence <220> <223> Synthetic DNA <400> 72 ttatttaatg atccaatgga gggggtgatt caggtaataa aaggcctt 48 <210> 73 <211> 48 <212> DNA <213> Artificial sequence <220> <223> Synthetic DNA <400> 73 ttatttaatg atccaatgga gggggtgatt caggtaataa aaggcact 48 <210> 74 <211> 48 <212> DNA <213> Artificial sequence <220> <223> Synthetic DNA <400> 74 ttatttaatg atccaatgga gggggtgatt caggtaataa aaggctta 48 <210> 75 <211> 48 <212> DNA <213> Artificial sequence <220> <223> Synthetic DNA <400> 75 ttatttaatg atccaatgga gggggtgatt caggtaataa aaggcttg 48 <210> 76 <211> 48 <212> DNA <213> Artificial sequence <220> <223> Synthetic DNA <400> 76 ttatttaatg atccaatgga gggggtgatt caggtaataa aaggcctc 48 <210> 77 <211> 48 <212> DNA <213> Artificial sequence <220> <223> Synthetic DNA <400> 77 ttatttaatg atccaatgga gggggtgatt caggtaataa aaggcacg 48 <210> 78 <211> 48 <212> DNA <213> Artificial sequence <220> <223> Synthetic DNA <400> 78 ttatttaatg atccaatgga gggggtgatt caggtaataa aagtcatg 48 <210> 79 <211> 48 <212> DNA <213> Artificial sequence <220> <223> Synthetic DNA <400> 79 ttatttaatg atccaatgga gggggtgatt caggtaataa aaggctrt 48 <210> 80 <211> 48 <212> DNA <213> Artificial sequence <220> <223> Synthetic DNA <400> 80 ttatttaatg atccaatgga gggggtgatt caggtaataa aaggcttr 48 <210> 81 <211> 48 <212> DNA <213> Artificial sequence <220> <223> Synthetic DNA <400> 81 ttatttaatg atccaatgga gggggtgatt caggtaataa aaggcagc 48 <210> 82 <211> 48 <212> DNA <213> Artificial sequence <220> <223> Synthetic DNA <400> 82 ttatttaatg atccaatgga gggggtgatt caggtaataa aaggcycg 48 <210> 83 <211> 48 <212> DNA <213> Artificial sequence <220> <223> Synthetic DNA <400> 83 ttatttaatg atccaatgga gggggtgatt caggtaataa aagtgatc 48 <210> 84 <211> 48 <212> DNA <213> Artificial sequence <220> <223> Synthetic DNA <400> 84 ttatttaatg atccaatgga gggggtgatt caggtaataa aagggagg 48 <210> 85 <211> 48 <212> DNA <213> Artificial sequence <220> <223> Synthetic DNA <400> 85 ttatttaatg atccaatgga gggggtgatt caggtaataa aaggctgc 48 <210> 86 <211> 48 <212> DNA <213> Artificial sequence <220> <223> Synthetic DNA <400> 86 ttatttaatg atccaatgga gggggtgatt caggtaataa aaggaacc 48 <210> 87 <211> 48 <212> DNA <213> Artificial sequence <220> <223> Synthetic DNA <400> 87 ttatttaatg atccaatgga gggggtgatt caggtaataa aaggctga 48 <210> 88 <211> 48 <212> DNA <213> Artificial sequence <220> <223> Synthetic DNA <400> 88 ttatttaatg atccaatgga gggggtgatt caggtaataa aaggctgg 48 <210> 89 <211> 48 <212> DNA <213> Artificial Sequence <220> <223> Synthetic DNA <400> 89 ttatttaatg atccaatgga gggggtgatt caggtaataa aaggggtg 48 <210> 90 <211> 48 <212> DNA <213> Artificial Sequence <220> <223> Synthetic DNA <400> 90 ttatttaatg atccaatgga gggggtgatt caggtaataa aaggtctg 48 <210> 91 <211> 48 <212> DNA <213> Artificial Sequence <220> <223> Synthetic DNA <400> 91 ttatttaatg atccaatgga gggggtgatt caggtaataa aagggaag 48 <210> 92 <211> 48 <212> DNA <213> Artificial Sequence <220> <223> Synthetic DNA <400> 92 ttatttaatg atccaatgga gggggtgatt caggtaataa aaggtcgt 48 <210> 93 <211> 48 <212> DNA <213> Artificial sequence <220> <223> Synthetic DNA <400> 93 ttatttaatg atccaatgga gggggtgatt caggtaataa aagttata 48 <210> 94 <211> 48 <212> DNA <213> Artificial sequence <220> <223> Synthetic DNA <400> 94 ttatttaatg atccaatgga gggggtgatt caggtaataa aaggctcg 48 <210> 95 <211> 48 <212> DNA <213> Artificial sequence <220> <223> Synthetic DNA <400> 95 ttatttaatg atccaatgga gggggtgatt caggcgataa aaggcgtt 48 <210> 96 <211> 367 <212> DNA <213> Artificial sequence <220> <223> PCR product <400> 96 ttatttaatg atccaatgga gggggtgatt caggtaataa aaggcactag tatggaatat 60 accaaaacat tgcgattcgt tattagcatg gatctttcaa gtaataaact tatcggagaa 120 ataccagttg agttaactgc ccttcatgcc ttggtgagtc tcaatttgtc taataatcat 180 cttattggac acattccgaa tagcattgga aacatgaaag ctttaaattc tctagatttc 240 tcgagaaacg agttaaatgg gttgatccct ccaagcattg gagctttgaa ttttttgagt 300 catttaaatt tgtcaaacaa caacttatca ggaccaattc caatcggaaa tcaattgaga 360 accctca 367 <210> 97 <211> 367 <212> DNA <213> Artificial sequence <220> <223> PCR product <400> 97 ttatttaatg atccaatgga gggggtgatt caggtaataa aaggcactcg tatggaatat 60 accaaaacat tgcgattcgt tattagcatg gatctttcaa gtaataaact tatcggagaa 120 ataccagttg agttaactgc ccttcatgcc ttggtgagtc tcaatttgtc taataatcat 180 cttattggac acattccgaa tagcattgga aacatgaaag ctttaaattc tctagatttc 240 tcgagaaacg agttaaatgg gttgatccct ccaagcattg gagctttgaa ttttttgagt 300 catttaaatt tgtcaaacaa caacttatca ggaccaattc caatcggaaa tcaattgaga 360 accctca 367 <210> 98 <211> 321 <212> DNA <213> Artificial sequence <220> <223> Digestion products <400> 98 ctagtatgga atataccaaa acattgcgat tcgttattag catggatctt tcaagtaata 60 aacttatcgg agaaatacca gttgagttaa ctgcccttca tgccttggtg agtctcaatt 120 tgtctaataa tcatcttatt ggacacattc cgaatagcat tggaaacatg aaagctttaa 180 attctctaga tttctcgaga aacgagttaa atgggttgat ccctccaagc attggagctt 240 tgaatttttt gagtcattta aatttgtcaa acaacaactt atcaggacca attccaatcg 300 gaaatcaatt gagaaccctc a 321 <210> 99 <211> twenty one <212> DNA <213> Artificial sequence <220> <223> Synthetic DNA <400> 99 aaaaggcatt agtatggaat a 21 <210> 100 <211> 41 <212> DNA <213> Artificial sequence <220> <223> Synthetic DNA <400> 100 ttcaggtaat aaaaggcatt agtatggaat ataccaaaac a 41 <210> 101 <211> 61 <212> DNA <213> Artificial sequence <220> <223> Synthetic DNA <400> 101 gagggggtga ttcaggtaat aaaaggcatt agtatggaat ataccaaaac attgcgattc 60 g 61 <210> 102 <211> 81 <212> DNA <213> Artificial sequence <220> <223> Synthetic DNA <400> 102 tgatccaatg gagggggtga ttcaggtaat aaaaggcatt agtatggaat ataccaaaac 60 attgcgattc gttattagca t 81
Claims
1. A method for screening stevia plants with high sweetness component content, characterized in that: The method comprises the step of detecting a mutation from C to A at a site corresponding to position 49 of SEQ ID NO: 1 from the genome of a test stevia plant.
2. The method according to claim 1, characterized in that The step of detecting mutations is performed using the dCAPS method or the TaqMan PCR method.
3. The method according to claim 1 or 2, characterized in that: The method further comprises the step of determining the content of sweet components in the test stevia plant tissue in which the mutation has been detected.
4. The method according to any one of claims 1 to 3, characterized in that The test stevia plant body belongs to an isolated group, which is obtained by mating parents at least one of which is a heterozygous parent with a mutation from C to A in the site corresponding to position 49 of sequence number 1, and the content of sweet components contained in the high-sweet component-containing stevia plant body is higher than the average value of the sweet component content of all individuals belonging to the aforementioned isolated group.
5. The method according to any one of claims 1 to 4, characterized in that: Sweet ingredients include steviol glycosides.
6. The method according to any one of claims 1 to 5, characterized in that: The stevia plant with high sweetness content is a non-genetically modified plant.
7. The method according to any one of claims 1 to 6, characterized in that: The tested stevia plants include stevia plants that have been subjected to mutagenesis treatment and their progeny plants.
8. A primer pair, characterized in that: The invention comprises the following forward primer and reverse primer: the forward primer comprises a sequence selected from sequence numbers 47 to 70 located at the 3' end and any continuous sequence extending from position 28 of sequence number 1 to the 5' end and attached to the 5' end of the aforementioned sequence in an arbitrarily selected manner; the reverse primer comprises a sequence complementary to any continuous sequence of more than 20 bases located from position 50 of sequence number 1 to the 3' end.
9. A kit comprising the primer pair and restriction enzyme according to claim 8, characterized in that: When the forward primer includes sequence number 47, the restriction enzyme is DdeI; when the forward primer includes sequence number 48, the restriction enzyme is MaeI or SpeI; when the forward primer includes sequence number 49, the restriction enzyme is AflII or MseI; when the forward primer includes sequence number 50, the restriction enzyme is Bce83I; when the forward primer includes sequence number 51, the restriction enzyme is BseMII; when the forward primer includes sequence number 52, the restriction enzyme is Bsi I; when the forward primer includes sequence number 53, the restriction enzyme is BspHI or Hpy178III; when the forward primer includes sequence number 54, the restriction enzyme is SfeI; when the forward primer includes sequence number 55, the restriction enzyme is SmlI; when the forward primer includes sequence number 56, the restriction enzyme is EcoP15I; when the forward primer includes sequence number 57, the restriction enzyme is AvaI; when the forward primer includes sequence number 58, the restriction enzyme is Bcl I; when the forward primer includes sequence number 59, the restriction enzyme is BseRI; when the forward primer includes sequence number 60, the restriction enzyme is CviRI or PstI; when the forward primer includes sequence number 61, the restriction enzyme is DrdII; when the forward primer includes sequence number 62, the restriction enzyme is Eco57I; when the forward primer includes sequence number 63, the restriction enzyme is GsuI; when the forward primer includes sequence number 64, the restriction enzyme is HphI; when When the forward primer includes sequence number 65, the restriction enzyme is Hpy188I; when the forward primer includes sequence number 66, the restriction enzyme is MboII; when the forward primer includes sequence number 67, the restriction enzyme is Pfl1108I; when the forward primer includes sequence number 68, the restriction enzyme is PsiI; when the forward primer includes sequence number 69, the restriction enzyme is TaqI or XhoI; when the forward primer includes sequence number 70, the restriction enzyme is StySKI.
10. A dried leaf of a plant, wherein the plant is a stevia plant with a high sweetness component content, characterized in that: There is a mutation from C to A in the site corresponding to position 49 of SEQ ID NO:
1.
11. The dried leaf according to claim 10, characterized in that The plant body is a non-genetically recombinant plant body.
12. A method for cultivating a stevia plant body having a high sweetness component content, characterized in that: The method comprises the step of hybridizing a stevia plant having a mutation from C to A at a site corresponding to position 49 of SEQ ID NO: 1 with a second stevia plant.
13. The method according to claim 12, characterized in that The second plant is a Stevia plant having a mutation from C to A at the site corresponding to position 49 of SEQ ID NO:
1.
14. A method for cultivating a stevia plant body having a high sweetness component content, characterized in that: The method comprises the step of introducing a mutation from C to A at a site corresponding to position 49 of sequence number 1 in the genome of the Stevia plant.
15. A method for producing a food or beverage, a sweetening composition, a spice or a pharmaceutical product, characterized in that: The invention comprises the steps of obtaining an extract containing sweet ingredients from a plant having a mutation from C to A at a site corresponding to position 49 of sequence number 1, or from seeds, tissues, dried leaves, tissue culture or cells of the plant, and adding the extract to the raw materials of food, beverage, sweetening composition, spice or medicine.
Citation Information
Patent Citations
High-intensity sweetener compositions containing vitamins and compositions sweetened therewith
JP2009517043A
Novel steviol glycosides
JP2012504552A
Stevia plants with increased rebaudioside d content
JP2016515814A
Steering control system
JP2018144512A
Polymorphism detection
US5858659A
